RxDoctor Payments Data

Richard Cooley, MD

Internal Medicine · Baton Rouge, LANPI 1245265552

Payments from drug & device makers

$293in general payments, 2019–2025

Across 11 payments — averaging $26.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$125
  • AbbVie$54
  • Pfizer$51
  • Novartis$17
  • Lilly USA, LLC$16
  • Pharmacyclics LLC, An Abbvie Company$16
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$293 in reported general payments places this provider in the 45th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$391,495
Medicare patients
594
Services billed
11,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide141$158,080
JardianceEmpagliflozin172$147,096
OzempicSemaglutide103$114,419
EliquisApixaban67$53,608
XareltoRivaroxaban44$45,691
TrulicityDulaglutide27$37,954
Repatha SureclickEvolocumab36$34,742
JanuviaSitagliptin Phosphate22$16,446
Atorvastatin Calcium1,835$13,838
JanumetSitagliptin Phos/Metformin Hcl17$13,372
Fiasp FlextouchInsulin Aspart (Niacinamide)13$10,182
InvokanaCanagliflozin14$8,541
SynthroidLevothyroxine Sodium120$8,416
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$7,752
Levothyroxine Sodium984$7,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$16$196,034168 claims
PfizerEliquis$51$53,60867 claims
AbbVieSynthroid, Linzess$54$15,482132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →